Cited by 477HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsGastric Cancer Management and Outcomes

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

Shattuck, David L., Miller, Jamie K., Carraway, Kermit L., Sweeney, Colleen·2008·Cancer Research

Open this paper in CoChat — free account

Abstract

Her2 is overexpressed in 20% to 30% of breast tumors and correlates with reduced disease-free and overall patient survival. Trastuzumab, a humanized monoclonal antibody directed against Her2, represents the first Her2-targeted therapy, which decreases the risk of relapse and prolongs patient survival. Resistance to trastuzumab, both inherent and treatment-acquired, represents a significant barrier to the effective treatment of Her2 (+) breast cancer. The Met receptor tyrosine kinase is aberrantly expressed in breast cancer and predicts poor patient prognosis. In this study, we find that Met is frequently expressed in Her2-overexpressing breast cancer cells, as well as Her2 (+) breast cancer. Importantly, Met contributes to trastuzumab resistance, as inhibition of Met sensitizes cells to trastuzumab-mediated growth inhibition, whereas Met activation protects cells against trastuzumab by abrogating p27 induction. Remarkably, Her2-overexpressing breast cancer cells rapidly up-regulate Met expression after trastuzumab treatment, promoting their own resistance. Our study suggests that a subset of Her2 (+) patients may benefit from combined inhibition of Her2 and Met.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-07-5962

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.
Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,640
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 739
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 636
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497
Trastuzumab: triumphs and tribulations
Nahta, R., & Esteva, F. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210379 · Cited by 343
P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells
Nahta, R., Takahashi, T., Ueno, N. T., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3900 · Cited by 298
Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer.
Yamashita, J.-I., Ogawa, M., Yamashita, S., Nomura, K., Kuramoto, M., Saishoji, T., & Shin, S.-I. (1994) · PubMed · Cited by 298
Equitable access to cancer services
Mandelblatt, J. S., Yabroff, K. R., & Kerner, J. F. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991201)86:11 · Cited by 269
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama, A. B., Hynes, N. E., & Lane, H. A. (2002) · PubMed · Cited by 249
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer
Harris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1304 · Cited by 245
Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Kang, J. J., Dolled-Filhart, M. P., Ocal, I. T., Singh, B., Lin, C.-Y., Dickson, R. B., Rimm, D. L., & Camp, R. L. (2003) · PubMed · Cited by 237
BindingDB Entry 50022503: A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
BindingDB (2025) · PubMed · doi:10.7270/q2dv1qm3 · Cited by 235
Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells
Lu, Y., Zi, X., & Pollak, M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11445 · Cited by 212
Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency
Lu, C., Wyszomierski, S. L., Tseng, L., Sun, M.-H., Lan, K., Neal, C. L., Mills, G. B., Hortobágyi, G. N., Esteva, F. J., & Yu, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2837 · Cited by 199
BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
Schiffer, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmct071828 · Cited by 198
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
Menéndez, J. A., Vázquez‐Martín, A., Colomer, R., Brunet, J., Carrasco‐Pancorbo, A., Garcı́a-Villalba, R., Fernández‐Gutiérrez, A., & Segura‐Carretero, A. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-80 · Cited by 190
Isolation of Two Human Tumor Epithelial Cell Lines From Solid Breast Carcinomas 2
Lasfargues, E. Y., Coutinho, W. G., & Redfield, E. S. (1978) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/61.4.967 · Cited by 189
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation
Diermeier, S., Horvath, G. L., Knuechel-Clarke, R., Hofstaedter, F., Szöllõsi, J., & Brockhoff, G. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.12.008 · Cited by 183
Utilization of polymerase chain reaction technology in the detection of solid tumors
Raj, G. V., Moreno, J. G., & Gomella, L. G. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980415)82:8 · Cited by 179
Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab
Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z. H., Mills, G. B., Mendelsohn, J., & Fan, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0589 · Cited by 170
Prognostic Significance of Co-expression of RON and MET Receptors in Node-Negative Breast Cancer Patients
Lee, W., Chen, H. H. W., Chow, N.-H., Su, W., Lin, P.-W., & Guo, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1761 · Cited by 135
Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma
Edakuni, G., Sasatomi, E., Satoh, T., Tokunaga, O., & Miyazaki, K. (2001) · Pathology International · doi:10.1046/j.1440-1827.2001.01182.x · Cited by 130
Tyrosine kinase signalling in breast cancer
Hynes, N. E. (2000) · Breast Cancer Research · doi:10.1186/bcr48 · Cited by 128
HGF Converts ErbB2/Neu Epithelial Morphogenesis to Cell Invasion
Khoury, H., Naujokas, M. A., Zuo, D., Sangwan, V., Frigault, M. M., Petkiewicz, S., Dankort, D. L., Muller, W. J., & Park, M. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0567 · Cited by 127
LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 Synergy
Shattuck, D. L., Miller, J. K., Laederich, M. B., Funes, M., Petersen, H. N., Carraway, K. L., & Sweeney, C. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00757-06 · Cited by 126
Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.
Wang, X., Le, P., Liang, C., Chan, J., Kiewlich, D., Miller, T. M., Harris, D., Sun, L., Rice, A. G., Vasile, S., et al. (2003) · PubMed · Cited by 114
Recombinant Human Insulin-like Growth Factor Binding Protein 3 Inhibits Growth of Human Epidermal Growth Factor Receptor-2–Overexpressing Breast Tumors and Potentiates Herceptin Activity In vivo
Jerome, L., Alami, N., Belanger, S., Pagé, V., Yu, Q., Paterson, J., Shiry, L., Pegram, M. D., & Leyland-Jones, B. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3555 · Cited by 106
Regulatory role of c-Met in insulin-like growth factor-I receptor–mediated migration and invasion of human pancreatic carcinoma cells
Bauer, T. W., Somcio, R., Fan, F., Liu, W., Johnson, M., Lesslie, D. P., Evans, D. B., Gallick, G. E., & Ellis, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0175 · Cited by 99
Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
Camirand, A., Lu, Y., & Pollak, M. (2002) · PubMed · Cited by 98
The Mucin Muc4 Potentiates Neuregulin Signaling by Increasing the Cell-surface Populations of ErbB2 and ErbB3
Funes, M., Miller, J. K., Lai, C., Carraway, K. L., & Sweeney, C. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603225200 · Cited by 88
Molecular pathology of primary and metastatic ductal pancreatic lesions
Ruggeri, B., Huang, L., Berger, D., Chang, H., Klein–Szanto, A. J., Goodrow, T. L., Wood, M., Obara, T., Heath, C. W., & Lynch, H. T. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4 · Cited by 71
Insulinlike Growth Factor-I???Mediated Migration and Invasion of Human Colon Carcinoma Cells Requires Activation of c-Met and Urokinase Plasminogen Activator Receptor
Bauer, T. W., Fan, F., Liu, W., Johnson, M., Parikh, N. U., Parry, G. C., Callahan, J. A., Mazar, A. P., Gallick, G. E., & Ellis, L. M. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000160699.59061.92 · Cited by 59
Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations.
Yao, Y., Jin, L., Fuchs, A., Joseph, A., Hastings, H. M., Goldberg, I. D., & Rosen, E. M. (1996) · Europe PMC (PubMed Central) · Cited by 56
Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer
Nagy, J., Curry, G., Hillan, K. J., McKay, I. C., Mallon, E., Purushotham, A. D., & George, W. D. (1996) · Surgical Oncology · doi:10.1016/s0960-7404(96)80017-x · Cited by 55
Differential expression of c‐Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue
Lindemann, K. Y., Resau, J. H., Nährig, J., Kort, E. J., Leeser, B., Annecke, K., Welk, A., Schäfer, J., Woude, G. F. V., Lengyel, E. R., et al. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02732.x · Cited by 52
C-erbB-2 in Serum of Patients with Breast Cancer
Harris, L. N., Lüftner, D., Jäger, W., & Robertson, J. F. R. (1999) · The International Journal of Biological Markers · doi:10.1177/172460089901400103 · Cited by 31
Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?
Normanno, N., Campiglio, M., Perrone, F., Luca, A. D., & Ménard, S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi325 · Cited by 11

Sorted by citations

Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 878

See all 477

Authors: Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C.
Affiliations: UC Davis Comprehensive Cancer Center (US)
ORCID: Carraway, Kermit L.
Sweeney, Colleen
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2008-03-01
Volume: 68
Issue: 5
Pages: 1471-1477
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-07-5962
OpenAlex: W2027684043
Cited by: 473
References: 43
Citations by year: 2026: 6 · 2025: 18 · 2024: 12 · 2023: 30 · 2022: 18 · 2021: 22 · 2020: 34 · 2019: 24 · 2018: 22 · 2017: 24 · 2016: 26 · 2015: 33 · 2014: 37 · 2013: 41 · 2012: 42
FWCI: 14.78
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA123541, R01CA118384, R01CA123541, CA118384)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords: MET receptor tyrosine kinase, trastuzumab resistance, HER2-positive breast cancer, combination therapy, MET inhibition, HER2-targeted therapy, drug resistance
MeSH terms: Trastuzumab, Antibodies, Monoclonal, Antineoplastic Agents, Breast, Breast Neoplasms, Humans, Models, Biological, Phosphorylation, Gene Expression Regulation, Neoplastic, Erb-b2 Receptor Tyrosine Kinases, Genes, erbB-2, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks